San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Kintara Therapeutics is raising $30,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Scott Praill played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kintara Therapeutics

Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients who are failing or resistant to current treatment regimens. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. Our platform strategy is built on a robust understanding of cancer biology. We use modern approaches in our laboratory studies to determine where we can solve problems in the treatment of drug and immune resistant cancer.

To learn more about Kintara Therapeutics, visit http://www.kintara.com/

Contact:
Scott Praill, Chief Financial Officer
858-350-4364

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved